BR112018011389A2 - ?composto, composição farmacêutica, regulador de atividade para um receptor de androgênio, e, agente preventivo ou terapêutico? - Google Patents
?composto, composição farmacêutica, regulador de atividade para um receptor de androgênio, e, agente preventivo ou terapêutico?Info
- Publication number
- BR112018011389A2 BR112018011389A2 BR112018011389-1A BR112018011389A BR112018011389A2 BR 112018011389 A2 BR112018011389 A2 BR 112018011389A2 BR 112018011389 A BR112018011389 A BR 112018011389A BR 112018011389 A2 BR112018011389 A2 BR 112018011389A2
- Authority
- BR
- Brazil
- Prior art keywords
- group
- alkyl
- heterocyclic
- cycloalkyl
- hydrogen atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
- C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C335/12—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C335/18—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
um composto representado pela fórmula (i) e tendo uma propriedade de modulação da atividade de um receptor de androgênio, ou um sal farmaceuticamente aceitável do composto. x representa s ou o; z representa (ra)n-a-(cr13r14)0-1-(cr11r12)0-1-; a representa um grupo arila ou um grupo heteroarila; r1 representa um grupo alquila, um grupo cicloalquila, um grupo alquenila; um grupo alquinila, um grupo alcoxialquila, um grupo arila, um grupo arilalquila, um grupo heterocíclico ou um grupo alquila heterocíclico; r2 representa um átomo de hidrogênio, um átomo de halogênio, um grupo alquila, um grupo cicloalquila, ou um grupo fenila; r3 representa um átomo de hidrogênio, um átomo de halogênio, um grupo alquila, um grupo cicloalquila, um grupo alcoxialquila, um grupo alquenila, um grupo alquinila, um grupo cicloalquenila, um grupo arila, um grupo arilalquila, um grupo heterocíclico, um grupo alquila heterocíclico, um grupo acila, um grupo cicloalquilcarbonila, um grupo benzoíla, um grupo espiroalquila, um grupo adamantila, um grupo silila ou r31r32nco-; r4 e r5 representam independentemente um átomo de hidrogênio, um átomo de halogênio, um grupo alquila, um grupo fenila ou um grupo cicloalquila.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015242065 | 2015-12-11 | ||
JP2015-242065 | 2015-12-11 | ||
PCT/JP2016/086784 WO2017099237A1 (ja) | 2015-12-11 | 2016-12-09 | アミノアゾール誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018011389A2 true BR112018011389A2 (pt) | 2018-12-04 |
Family
ID=59013300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018011389-1A BR112018011389A2 (pt) | 2015-12-11 | 2016-12-09 | ?composto, composição farmacêutica, regulador de atividade para um receptor de androgênio, e, agente preventivo ou terapêutico? |
Country Status (20)
Country | Link |
---|---|
US (1) | US10689354B2 (pt) |
EP (1) | EP3388425B1 (pt) |
JP (1) | JP6456520B2 (pt) |
KR (1) | KR20180088412A (pt) |
CN (1) | CN108368068A (pt) |
AR (1) | AR107040A1 (pt) |
AU (1) | AU2016366443A1 (pt) |
BR (1) | BR112018011389A2 (pt) |
CA (1) | CA2997689A1 (pt) |
CL (1) | CL2018001537A1 (pt) |
CO (1) | CO2018005873A2 (pt) |
HK (1) | HK1259107A1 (pt) |
IL (1) | IL259900A (pt) |
MX (1) | MX2018007000A (pt) |
PH (1) | PH12018500892A1 (pt) |
RU (1) | RU2018120308A (pt) |
SG (1) | SG11201804359SA (pt) |
TW (1) | TW201733979A (pt) |
WO (1) | WO2017099237A1 (pt) |
ZA (1) | ZA201802194B (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023217095A1 (en) * | 2022-05-09 | 2023-11-16 | Synrx Therapeutics (Hangzhou) Co., Ltd. | Heterocyclic compound, pharmaceutical composition and use thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4215878A1 (de) * | 1992-05-14 | 1993-11-18 | Bayer Ag | Sulfonylierte Carbonsäureamide |
US5256632A (en) | 1990-05-30 | 1993-10-26 | Bayer Aktiengesellschaft | Herbicidal sulphonylated carboxamides |
EP0752421B1 (en) * | 1995-07-07 | 2005-10-12 | AstraZeneca AB | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists |
EP0882718B1 (en) | 1995-12-28 | 2005-08-31 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
WO1998015530A1 (fr) * | 1996-10-08 | 1998-04-16 | Fujisawa Pharmaceutical Co., Ltd. | Derives d'indol |
WO1999000359A1 (fr) * | 1997-06-27 | 1999-01-07 | Fujisawa Pharmaceutical Co., Ltd. | Derives de noyau aromatique |
TW453999B (en) | 1997-06-27 | 2001-09-11 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
US20030138416A1 (en) | 2001-12-03 | 2003-07-24 | Jesper Lau | Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
JP4881559B2 (ja) * | 2002-06-27 | 2012-02-22 | ノボ・ノルデイスク・エー/エス | 治療薬としてのアリールカルボニル誘導体 |
US7622592B2 (en) * | 2002-11-01 | 2009-11-24 | Merck & Co., Inc. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
JP2007523868A (ja) * | 2003-07-10 | 2007-08-23 | アキリオン ファーマシューティカルズ,インコーポレーテッド | ウイルス複製の阻害薬として有用な置換アリールチオウレア誘導体類 |
GB0508463D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
BRPI0611187A2 (pt) | 2005-06-03 | 2010-08-24 | Xenon Pharmaceuticals Inc | derivados aminotiazàis como inibidores da estearoil-coa desaturase humana |
JP4884072B2 (ja) * | 2006-05-12 | 2012-02-22 | 三井化学アグロ株式会社 | 複素環誘導体ならびにその殺虫剤としての使用方法 |
CL2008001933A1 (es) * | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
WO2010012793A1 (en) * | 2008-08-01 | 2010-02-04 | Bayer Cropscience Sa | Fungicide aminothiazole derivatives |
US8686044B2 (en) | 2008-08-13 | 2014-04-01 | Mitsui Chemicals Agro, Inc. | Amide derivative, pest control agent containing the amide derivative, and use of the amide derivative |
VN27368A1 (en) * | 2008-08-13 | 2011-09-26 | Mitsui Chemicals Agro Inc | Amide derivative, pest control agent containing the amide derivative and use of the pest control agent |
MX2014013758A (es) | 2012-05-11 | 2015-02-05 | Abbvie Inc | Derivados de tiazolcarboxamida para usarse como inhibidores de nampt. |
JP2015178458A (ja) * | 2012-07-25 | 2015-10-08 | 杏林製薬株式会社 | ベンゼン環縮合含窒素5員複素環式化合物、またはその薬理学的に許容される塩 |
-
2016
- 2016-12-09 BR BR112018011389-1A patent/BR112018011389A2/pt not_active Application Discontinuation
- 2016-12-09 CA CA2997689A patent/CA2997689A1/en not_active Abandoned
- 2016-12-09 JP JP2017555169A patent/JP6456520B2/ja active Active
- 2016-12-09 MX MX2018007000A patent/MX2018007000A/es unknown
- 2016-12-09 EP EP16873130.5A patent/EP3388425B1/en active Active
- 2016-12-09 AU AU2016366443A patent/AU2016366443A1/en not_active Abandoned
- 2016-12-09 WO PCT/JP2016/086784 patent/WO2017099237A1/ja active Application Filing
- 2016-12-09 RU RU2018120308A patent/RU2018120308A/ru unknown
- 2016-12-09 KR KR1020187016201A patent/KR20180088412A/ko unknown
- 2016-12-09 SG SG11201804359SA patent/SG11201804359SA/en unknown
- 2016-12-09 TW TW105140912A patent/TW201733979A/zh unknown
- 2016-12-09 US US16/060,701 patent/US10689354B2/en active Active
- 2016-12-09 CN CN201680072253.7A patent/CN108368068A/zh active Pending
- 2016-12-12 AR ARP160103787A patent/AR107040A1/es unknown
-
2018
- 2018-04-04 ZA ZA2018/02194A patent/ZA201802194B/en unknown
- 2018-04-26 PH PH12018500892A patent/PH12018500892A1/en unknown
- 2018-06-07 CO CONC2018/0005873A patent/CO2018005873A2/es unknown
- 2018-06-07 IL IL259900A patent/IL259900A/en unknown
- 2018-06-08 CL CL2018001537A patent/CL2018001537A1/es unknown
-
2019
- 2019-01-30 HK HK19101612.5A patent/HK1259107A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20180088412A (ko) | 2018-08-03 |
ZA201802194B (en) | 2019-01-30 |
AU2016366443A1 (en) | 2018-05-10 |
US20190031628A1 (en) | 2019-01-31 |
EP3388425A4 (en) | 2019-08-21 |
CA2997689A1 (en) | 2017-06-15 |
AR107040A1 (es) | 2018-03-14 |
JPWO2017099237A1 (ja) | 2018-04-12 |
US10689354B2 (en) | 2020-06-23 |
EP3388425A1 (en) | 2018-10-17 |
RU2018120308A3 (pt) | 2019-12-03 |
TW201733979A (zh) | 2017-10-01 |
CN108368068A (zh) | 2018-08-03 |
CO2018005873A2 (es) | 2018-06-20 |
RU2018120308A (ru) | 2019-12-03 |
JP6456520B2 (ja) | 2019-01-23 |
CL2018001537A1 (es) | 2018-07-20 |
MX2018007000A (es) | 2018-08-01 |
IL259900A (en) | 2018-07-31 |
SG11201804359SA (en) | 2018-06-28 |
HK1259107A1 (zh) | 2019-11-22 |
WO2017099237A1 (ja) | 2017-06-15 |
EP3388425B1 (en) | 2020-08-05 |
PH12018500892A1 (en) | 2018-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
SG11201805286RA (en) | α,β-UNSATURATED AMIDE COMPOUND | |
PH12018500591A1 (en) | Heterocyclic compounds and uses thereof | |
CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
PH12020500673A1 (en) | Compounds | |
TW201613911A (en) | Heterocyclic compounds and uses thereof | |
GEP20186887B (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
MX2016011992A (es) | Derivados de piperidina-diona. | |
CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
BR112016001979A2 (pt) | composto de tetrazolinona e uso do mesmo | |
BR112015016580A2 (pt) | composto heterocíclico contendo nitrogênio ou sal deste | |
MY193597A (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
CY1121626T1 (el) | Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου | |
BR112013018732A2 (pt) | novos derivados de amida de aril-benzocicloalquila | |
MX2020003604A (es) | Derivados heterociclicos como pesticidas. | |
MX2016007566A (es) | Derivados de amina ciclica de fenoxietilo y su actividad como moduladores de receptor ep4. | |
MX2017005158A (es) | Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk). | |
MX2017002275A (es) | Derivado de azaindol que tiene actividad activadora de proteina cinasa activada por monofosfato de adenosina (ampk). | |
GEP20227389B (en) | Microbiocidal thiazole derivatives | |
MX2016005324A (es) | Composiciones pesticidas y metodos relacionados. | |
BR112015009650A2 (pt) | composição e método para exterminar parasita animal | |
MX2020004842A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
BR112018011389A2 (pt) | ?composto, composição farmacêutica, regulador de atividade para um receptor de androgênio, e, agente preventivo ou terapêutico? | |
PH12018500668A1 (en) | Therapeutic compounds and methods of use thereof | |
BR112017014682A2 (pt) | composto carbamato e seu uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |